广泛期小细胞肺癌一线治疗现状及研究进展

Current Status and Research Progress of First-line Treatment of Extensive Small Cell Lung Cancer

小细胞肺癌(small cell lung cancer,SCLC)恶性程度极高,易早期发生复发转移,预后差。以化疗为主要治疗方式的广泛期SCLC(extensive stage SCLC,ES-SCLC)中位生存期仅8~12个月。免疫治疗联合化疗的综合治疗模式使ES-SCLC患者的生存期较之前有了一定的提高,但两项大规模的临床研究CASPIAN和IMpower133都仅仅提高了不到3个月的生存期。本文将对ES-SCLC的一线治疗现状及研究进展进行综述。

Small cell lung cancer(SCLC)is highly malignant,prone to early recurrence and metastasis,and has a poor prognosis.The median survival for extensive stage SCLC(ES-SCLC)with chemotherapy as the main treatment method is only 8 to 12 months.The combined treatment mode of immunotherapy combined with chemotherapy improved the survival of patients with ES-SCLC to a certain extent than before,but two large-scale clinical studies CASPIAN and IMpower133 only improved the survival of less than 3 months.This article will review the current status and research progress of first-line treatment of ES-SCLC.